SCHEMBL2701746

SCHEMBL2701746

O=C(COc1ccccc1)N1CCC(Cc2ccc(F)cc2)(C(=O)O)CC1

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.57
KMT2A Q03164 3/20 0.57
POLB P06746 3/20 0.56
GAA P10253 2/20 0.53
USP2 O75604 1/20 0.53
FKBP1A P62942 1/20 0.52
ALDH1A1 P00352 3/20 0.50
SMN1; SMN2 Q16637 3/20 0.50
L3MBTL1 Q9Y468 2/20 0.50
MAPT P10636 1/20 0.50
RAB9A P51151 1/20 0.50
ENPP2 Q13822 1/20 0.47
LMNA P02545 2/20 0.47
KDM4E B2RXH2 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
GHSR Q92847 1/20 0.47
ME2 P23368 1/20 0.46
ME1 P48163 1/20 0.46
ME3 Q16798 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2700022 0.92 MEN1 (0.64) MEN1KMT2APOLBGAAUSP2
SCHEMBL5317162 0.90 POLB (0.54) MEN1KMT2APOLBFKBP1AALDH1A1
SCHEMBL2474188 0.85 KMT2A (0.51) MEN1KMT2APOLBGAAUSP2
SCHEMBL2699816 0.84 MEN1 (0.67) MEN1KMT2APOLBGAAUSP2
SCHEMBL2702690 0.83 HSD11B1 (0.53) MEN1KMT2APOLBGAAUSP2
SCHEMBL2471698 0.82 MEN1 (0.48) MEN1KMT2APOLBGAAUSP2
SCHEMBL8642210 0.81 DRD2 (0.52) MEN1KMT2AALDH1A1TDP1
SCHEMBL2702117 0.81 GFER (0.60) MEN1KMT2APOLBFKBP1AALDH1A1
SCHEMBL2471606 0.81 MEN1 (0.54) MEN1KMT2APOLBGAAFKBP1A
SCHEMBL14494792 0.81 FKBP1A (0.60) MEN1KMT2APOLBGAAUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2228065-B1 Heterocyclo inhibitors of potassium channel function BRISTOL MYERS SQUIBB CO (US) 2012-12-26 EP disclosed
EP-1501467-B1 HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION BRISTOL MYERS SQUIBB CO (US) 2012-05-09 EP disclosed
EP-2228065-A2 Heterocyclo inhibitors of potassium channel function Bristol-Myers Squibb Company (US) 2010-09-15 EP disclosed
US-20090312307-A1 HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION BRISTOL-MYERS SQUIBB COMPANY 2009-12-17 US disclosed
US-7582654-B2 Heterocyclo inhibitors of potassium channel function BRISTOL-MYERS SQUIBB COMPANY (US) 2009-09-01 US disclosed
US-7005436-B2 Heterocyclo inhibitors of potassium channel function BRISTOL MYERS SQUIBB COMPANY (US) 2006-02-28 US disclosed
US-20060014792-A1 Heterocyclo inhibitors of potassium channel function LLOYD JOHN 2006-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060014792-A1 Heterocyclo inhibitors of potassium channel function KCNJ2, KCNH2, KCNQ5 MEN1 3501/4885KMT2A 957/4885POLB 4413/4885
US-20090312307-A1 HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION KCNJ2, KCNH2, KCNQ5 MEN1 3501/4885KMT2A 957/4885POLB 4413/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.